Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23


1303 - Tumour histology and primary site but not MDM2 amplification levels are prognostic for clinical outcomes in well differentiated and dedifferentiated liposarcoma. (487O)


18 Nov 2017




Pathology/Molecular Biology;  Soft Tissue Sarcomas


Winston Chew


Annals of Oncology (2017) 28 (suppl_10): x149-x152. 10.1093/annonc/mdx675


W.H.W. Chew1, J.Y. Chan1, W.L. Goh1, J.H.C. Lim2, S.H. Tan2, N. Somasundaram1, E.Y.L. Poon1, A.S.T. Lim3, M.H. Tan4, K.C. Soo5, M. Teo5, T.K.Y. Tay6, S. Selvarajan6, K. Sittampalam6, R. Quek1

Author affiliations

  • 1 Division Of Medical Oncology, National Cancer Centre Singapore, 169610 - Singapore/SG
  • 2 Division Of Clinical Trials & Epidemiological Sciences, National Cancer Centre Singapore, 169610 - Singapore/SG
  • 3 Department Of Molecular Pathology, Singapore General Hospital, Singapore/SG
  • 4 Department Of Orthopaedic Surgery, Singapore General Hospital, 169610 - Singapore/SG
  • 5 Division Of Surgical Oncology, National Cancer Centre Singapore, 169610 - Singapore/SG
  • 6 Department Of Anatomical Pathology, Singapore General Hospital, Singapore/SG


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1303


MDM2, an oncogene and p53 inhibitor is consistently amplified in well differentiated (WD) and dedifferentiated (DD) liposarcomas (LPS). Although previous reports have deemed fluorescent in situ hybridization (FISH) of MDM2 as the diagnostic gold standard for WD/DDLPS, the prognostic utility of this biomarker is less well established. This study aims to examine MDM2 amplification as a prognostic factor in LPS.


A retrospective review of clinical records was done to identify patients (pts) with primary LPS that were curatively resected and assessed for MDM2 via FISH. Dual color MDM2/CEP 12 probes were applied to FFPE tissue sections. Signals from 60 non–overlapping nuclei were counted for copy numbers of MDM2 and CEP 12. MDM2 gene amplification was defined as the ratio of MDM2 signals to CEP 12 signals. Receiver operating curve analysis was used to determine a cut-off for high MDM2 ratio (>9.1). Progression free survival (PFS) was assessed from time of resection to relapse or death. Survival analysis was done using Kaplan-Meier and multivariable cox models.


55 pts consisting of 20 DDLPS and 35 WDLPS were identified. Higher levels of MDM2 ratio was associated with retroperitoneal tumour site (8.1 vs 5.4, Mann-Whitney; p=0.023). No statistical difference in MDM2 ratio was seen in other clinical features; including age of diagnosis, performance status, resection margins, tumour histology and size. On univariate survival analysis, DDLPS (HR 11.163; 95%CI 3.935-31.663; p


In this cohort of WD and DD LPS pts, tumour histology and primary site but not MDM2 amplification level, were prognostic for clinical outcomes.

Clinical trial identification

Legal entity responsible for the study

SingHealth Centralised Institutional Review Board




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.